Unaltered lactate and glucose transporter levels in the MPTP mouse model of Parkinson's disease

Journal of Parkinson's Disease

Volumn 3, Issue 3, 2013, Pages 371-385

  Puchades, Maja ^a   Sogn, Carl Johan ^a   Maehlen, Jan ^b   Bergersen, Linda H ^a,c,d,e   Gundersen, Vidar ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Brain; Energy metabolism; Monocarboxylic acid transporters; Neurodegenerative disease; Parkinson's disease

Indexed keywords

GLUCOSE TRANSPORTER 1; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN LEVEL; CELL DENSITY; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORPUS STRIATUM; ELECTRON MICROSCOPY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA; VASCULAR ENDOTHELIUM;

ANIMALS; ASTROCYTES; BRAIN CHEMISTRY; FLUORESCENT ANTIBODY TECHNIQUE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; MONOCARBOXYLIC ACID TRANSPORTERS; MPTP POISONING; NEOSTRIATUM; PARKINSON DISEASE; SUBSTANTIA NIGRA; SYMPORTERS; TYROSINE 3-MONOOXYGENASE;

EID: 84888867481     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130190     Document Type: Article

References (63)

1. Olanow CW, & TattonW G (1999) Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci, 22, 123-144
2. Nicklas WJ, Vyas I, & Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-Tetrahydropyridine Life Sci, 36(26), 2503-2508
3. Langston JW, Ballard P, Tetrud JW, & Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidineanalog synthesis. Science, 219(4587), 979-980
4. Blesa J, Phani S, Jackson-Lewis V, & Przedborski S (2012) Classic and new animal models of Parkinson's disease. J Biomed Biotechnol, 2012, 845618, 10 pages, doi: 10.1155/2012/845618
5. Hirsch EC, Jenner P, & Przedborski S (2013) Pathogenesis of Parkinson's disease. Mov Disord, 28(1), 24-30
6. Exner N, Lutz AK, Haass C, & Winklhofer KF (2012) Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and pathophysiological consequences. EMBO J, 31(14), 3038-3062
7. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, Zanella F, & Hilker R (2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain, 132(Pt 12), 3285-3297
8. McGeer PL, Itagaki S, Boyes BE,&McGeerE G (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38(8), 1285-1291
9. McGeer PL, & McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord, 23(4), 474-483
10. Bowen BC, Block RE, Sanchez-Ramos J, Pattany PM, Lampman DA, Murdoch JB, & Quencer RM (1995) Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol, 16(1), 61-68
11. Henchcliffe C, Shungu DC, Mao X, Huang C, NirenbergMJ, Jenkins BG, & Beal MF (2008) Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease. Ann N Y Acad Sci, 1147, 206-220
12. Gao HC, Zhu H, Song CY, Lin L, Xiang Y, Yan ZH, Bai GH, Ye FQ, & Li XK (2013) Metabolic Changes Detected by Ex Vivo High Resolution (1)HNMRSpectroscopy in the Striatum of 6-OHDA-Induced Parkinson's Rat. Mol Neurobiol, 47(1), 123-130
13. Jenkins BG, Brouillet E, Chen YC, Storey E, Schulz JB, Kirschner P, Beal MF, & Rosen BR (1996) Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab, 16(3), 450-461
14. Koga K, Mori A, Ohashi S,Kurihara N, KitagawaH, Ishikawa M, Mitsumoto Y, & Nakai M (2006) HMRS identifies lactate rise in the striatum of MPTP-Treated C57BL/6 mice. Eur J Neurosci, 23(4), 1077-1081
15. Borghammer P, Chakravarty M, Jonsdottir KY, Sato N, Matsuda H, Ito K, Arahata Y, Kato T,&Gjedde A (2010) Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: Probably even at early disease stages. Brain Struct Funct, 214(4), 303-317
16. Bergersen LH (2007) Is lactate food for neurons? Comparison of monocarboxylate transporter subtypes in brain and muscle. Neuroscience, 145(1), 11-19
17. Rafiki A, Boulland JL, Halestrap AP, Ottersen OP, & Bergersen L (2003) Highly differential expression of the monocarboxylate transporters MCT2 and MCT4 in the developing rat brain. Neuroscience, 122(3), 677-688
18. Gerhart DZ, Enerson BE, ZhdankinaOY, Leino RL,&Drewes LR (1997) Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats Am J Physiol, 273(1 Pt 1), E207-E213
19. Rinholm JE, Hamilton NB, Kessaris N, Richardson WD, Bergersen LH, & Attwell D (2011) Regulation of oligodendrocyte development and myelination by glucose and lactate. J Neurosci, 31(2), 538-548
20. Lauritzen F, de Lanerolle NC, Lee TS, Spencer DD, Kim JH, Bergersen LH, & Eid T (2011) Monocarboxylate transporter 1 is deficient on microvessels in the human epileptogenic hippocampus. Neurobiol Dis, 41(2), 577-584
21. Lauritzen F, Heuser K, de Lanerolle NC, Lee TS, Spencer DD, Kim JH, Gjedde A, Eid T, & Bergersen LH (2012) Redistribution of monocarboxylate transporter 2 on the surface of astrocytes in the human epileptogenic hippocampus. Glia, 60(7), 1172-1181
22. Bergersen L, Waerhaug O, Helm J, Thomas M, Laake P, Davies AJ,Wilson MC, Halestrap AP, & Ottersen OP (2001) A novel postsynaptic density protein: The monocarboxylate transporter MCT2 is co-localized with delta-glutamate receptors in postsynaptic densities of parallel fiber-Purkinje cell synapses. Exp Brain Res, 136(4), 523-534
23. Bergersen LH, Magistretti PJ, & Pellerin L (2005) Selective postsynaptic co-localization of MCT2 with AMPA receptor GluR2/3 subunits at excitatory synapses exhibiting AMPA receptor trafficking. Cereb Cortex, 15(4), 361-370
24. Pierre K, Magistretti PJ,&Pellerin L (2002) MCT2 is a major neuronal monocarboxylate transporter in the adult mouse brain J Cereb Blood Flow Metab, 22(5), 586-595
25. Simpson IA, Carruthers A, & Vannucci SJ (2007) Supply and demand in cerebral energy metabolism: The role of nutrient transporters. J Cereb Blood Flow Metab, 27(11), 1766-1791
26. Cornford EM, Hyman S, & Swartz BE (1994) The human brain GLUT1 glucose transporter: Ultrastructural localization to the blood-brain barrier endothelia. J Cereb Blood Flow Metab, 14(1), 106-112
27. Cornford EM, & Hyman S (2005) Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy. NeuroRx, 2(1), 27-43
28. Gronlund KM, Gerhart DZ, Leino RL, McCall AL,&Drewes LR (1996) Chronic seizures increase glucose transporter abundance in rat brain J Neuropathol Exp Neurol, 55(7), 832-840
29. Jackson-Lewis V, & Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc, 2(1), 141-151
30. Tatton NA, & Kish SJ (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-Tetrahydropyridine- Treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining Neuroscience, 77(4), 1037-1048
31. Cortes-Campos C, Elizondo R, Carril C, Martinez F, Boric K, Nualart F, & Garcia-Robles MA (2013) MCT2 expression and lactate influx in anorexigenic and orexigenic neurons of the arcuate nucleus. PLoS One, 8(4), e62532
32. Nunez-Parra A, Cortes-Campos C, Bacigalupo J, Garcia Mde L, Nualart F, & Reyes JG (2011) Expression and distribution of facilitative glucose (GLUTs) and monocarboxylate/ H+(MCTs) transporters in rat olfactory epithelia. Chem Senses, 36(9), 771-780
33. Lauritzen F, Perez EL, Melillo ER, Roh JM, Zaveri HP, Lee TS, Wang Y, Bergersen LH, & Eid T (2012) Altered expression of brain monocarboxylate transporter 1 in models of temporal lobe epilepsy. Neurobiol Dis, 45(1), 165-176
34. Yamamoto DL, Csikasz RI, Li Y, Sharma G, Hjort K, Karlsson R, & Bengtsson T (2008) Myotube formation on micro-patterned glass: Intracellular organization and protein distribution in C2C12 skeletal muscle cells. J Histochem Cytochem, 56(10), 881-892
35. Yan J, Zhou B, Taheri S,&Shi H (2011) Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and bloodbrain barrier damage in a rat model of ischemic stroke. PLoS One, 6(11), e27798
36. Hsu SM, Raine L, & Fanger H (1981) Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem, 29(4), 577-580
37. Medin T, Owe SG, Rinholm JE, Larsson M, Sagvolden T, Storm-Mathisen J, & Bergersen LH (2011) Dopamine D5 receptors are localized at asymmetric synapses in the rat hippocampus. Neuroscience, 192, 164-171
38. Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, et al. (1988) Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS, 96(5), 379-394
39. Bergersen LH, Storm-Mathisen J, & Gundersen V (2008) Immunogold quantification of amino acids and proteins in complex subcellular compartments. Nat Protoc, 3(1), 144-152
40. Larsson M & Broman J (2005) Different basal levels of CaMKII phosphorylated at Thr286/287 at nociceptive and low-Threshold primary afferent synapses. Eur J Neurosci, 21(9), 2445-2458
41. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, & Almer G (2000) The parkinsonian toxin MPTP: Action and mechanism. Restor Neurol Neurosci, 16(2), 135-142
42. Gerhart DZ, Enerson BE, ZhdankinaOY, Leino RL,&Drewes LR (1998) Expression of the monocarboxylate transporter MCT2 by rat brain glia. Glia, 22(3), 272-281
43. Hanu R, McKenna M, O'Neill A, Resneck WG, & Bloch RJ (2000) Monocarboxylic acid transporters, MCT1 and MCT2, in cortical astrocytes in vitro and in vivo. Am J Physiol Cell Physiol, 278(5), C921-C930
44. Pierre K, Chatton JY, Parent A, Repond C, Gardoni F, Di Luca M, & Pellerin L (2009) Linking supply to demand: The neuronal monocarboxylate transporter MCT2 and the alpha-Amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid receptor GluR2/3 subunit are associated in a common trafficking process. Eur J Neurosci, 29(10), 1951-1963
45. Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, & Crossman AR (1989) Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-Tetrahydropyridine Neuroscience, 32(1), 213-226
46. Palombo E, Porrino LJ, Bankiewicz KS, Crane AM, Sokoloff L, & Kopin IJ (1990) Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J Neurosci, 10(3), 860-869
47. Brownell AL, Canales K, Chen YI, Jenkins BG, Owen C, Livni E, Yu M, Cicchetti F, Sanchez-Pernaute R, & Isacson O (2003) Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model. Neuroimage, 20(2), 1064-1075
48. Kuhl DE, Metter EJ, & Riege WH (1984) Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method. Ann Neurol, 15(5), 419-424
49. Pappata S, Santangelo G, Aarsland D, Vicidomini C, Longo K, Bronnick K, Amboni M, Erro R, Vitale C, Caprio MG, Pellecchia MT, Brunetti A, De Michele G, Salvatore M, & Barone P (2011) Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology, 77(14), 1357-1362
50. Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M, McGeer PL, Phillips AG, Tsui JK, & Calne DB (1992) Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol, 49(12), 1262-1268
51. Tang CC, Poston KL, Dhawan V, & Eidelberg D (2010) Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci, 30(3), 1049-1056
52. Wolfson LI, Leenders KL, Brown LL,&Jones T (1985) Alterations of regional cerebral blood flowand oxygen metabolism in Parkinson's disease. Neurology, 35(10), 1399-1405
53. Mohr E, Mann UM, Miletich RS, Sampson M, Goldberg TE, Grimes JD, & Chase TN (1992) Neuropsychological and glucose metabolic profiles in asymmetric Parkinson's disease. Can J Neurol Sci, 19(2), 163-169
54. Podell M, Hadjiconstantinou M, Smith MA, & Neff NH (2003) Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. Exp Neurol, 179(2), 159-166
55. Moreira TJ, Pierre K, Maekawa F, Repond C, Cebere A, Liljequist S, & Pellerin L (2009) Enhanced cerebral expression of MCT1 and MCT2 in a rat ischemia model occurs in activated microglial cells. J Cereb Blood Flow Metab, 29(7), 1273-1283
56. Wang Y, Guo SZ, Bonen A, Li RC, Kheirandish-Gozal L, Zhang SX, Brittian KR, & Gozal D (2011) Monocarboxylate transporter 2 and stroke severity in a rodent model of sleep apnea. J Neurosci, 31(28), 10241-10248
57. McCall AL, Van Bueren AM, Nipper V, Moholt-Siebert M, Downes H, & Lessov N (1996) Forebrain ischemia increases GLUT1 protein in brain microvessels and parenchyma. J Cereb Blood Flow Metab, 16(1), 69-76
58. Chen C, Pore N, Behrooz A, Ismail-Beigi F,&Maity A (2001) Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem, 276(12), 9519-9525
59. Halestrap AP (2013) The SLC16 gene family-structure, role and regulation in health and disease. Mol Aspects Med, 34(2-3), 337-349
60. Buyse M, Sitaraman SV, Liu X, Bado A, & Merlin D (2002) Luminal leptin enhances CD147/MCT-1-mediated uptake of butyrate in the human intestinal cell line Caco2-BBE. J Biol Chem, 277(31), 28182-28190
61. Pierre K, Parent A, Jayet PY, Halestrap AP, Scherrer U,&Pellerin L (2007) Enhanced expression of three monocarboxylate transporter isoforms in the brain of obese mice J Physiol, 583(Pt 2), 469-486
62. Enoki T, Yoshida Y, Lally J, Hatta H, & Bonen A (2006) Testosterone increases lactate transport, monocarboxylate transporter (MCT) 1 and MCT4 in rat skeletal muscle. J Physiol, 577(Pt 1), 433-443
63. Robinet C, & Pellerin L (2010) Brain-derived neurotrophic factor enhances the expression of the monocarboxylate transporter 2 through translational activation in mouse cultured cortical neurons. J Cereb Blood Flow Metab, 30(2), 286-298